Why the study?
Does intravenous recombinant tissue-type plasminogen activator improve outcomes in patients with mild but disabling stroke symptoms?
Population
32 patients presenting with mild but disabling stroke symptoms
Design
Cohort
Follow-up
3 months
Authors
Loading...
Supports thrombolysis in mild disabling stroke per guidelines; leaves open randomized confirmation of net benefit.
Does intravenous recombinant tissue-type plasminogen activator improve outcomes in patients with mild but disabling stroke symptoms?
Intravenous thrombolysis appears safe and effective in patients with mild but disabling stroke symptoms, supporting current guidelines that do not set a lower NIHSS limit.
Köhrmann et al. (2008) studied this question.